Cargando…

Natural Compound Shikonin Is a Novel PAK1 Inhibitor and Enhances Efficacy of Chemotherapy against Pancreatic Cancer Cells

Shikonin is the main component of root extracts from the Chinese herbal medicine Lithospermum erythrorhizon, which is commonly used for the treatment of various diseases including cancer. Previous research showed that shikonin suppressed pancreatic cancer growth; nevertheless, its molecular targets...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Wenjing, Sun, Xiaoyan, Gao, Yang, Lu, Man, Zhu, Lingxia, Wang, Dawei, Hu, Chunping, Chen, Jiao, Cao, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102431/ https://www.ncbi.nlm.nih.gov/pubmed/35566098 http://dx.doi.org/10.3390/molecules27092747

Ejemplares similares

Identification of a novel PAK1 inhibitor to treat pancreatic cancer
por: Wang, Jiaqi, et al.
Publicado: (2020)

Natural Plant-Derived Compounds in Food and Cosmetics: A Paradigm of Shikonin and Its Derivatives
por: Malik, Sonia, et al.
Publicado: (2023)

Effect of Shikonin Against Candida albicans Biofilms
por: Yan, Yu, et al.
Publicado: (2019)

In Vitro Induction of Erythrocyte Phosphatidylserine Translocation by the Natural Naphthoquinone Shikonin
por: Lupescu, Adrian, et al.
Publicado: (2014)

Control of Foodborne Staphylococcus aureus by Shikonin, a Natural Extract
por: Wan, Yangli, et al.
Publicado: (2021)

Mechanisms Behind the Inhibition of Lung Adenocarcinoma Cell by Shikonin
por: Lan, Wenjing, et al.
Publicado: (2014)

Functional Deficits in Pak5, Pak6 and Pak5/Pak6 Knockout Mice
por: Furnari, Melody A., et al.
Publicado: (2013)

Natural Compound Shikonin Induces Apoptosis and Attenuates Epithelial to Mesenchymal Transition in Radiation-Resistant Human Colon Cancer Cells
por: Shilnikova, Kristina, et al.
Publicado: (2022)

Natural Shikonin Potentially Alters Intestinal Flora to Alleviate Acute Inflammation
por: Liang, Ying, et al.
Publicado: (2023)

Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms in vitro and in vivo
por: Tang, Jian-Cai, et al.
Publicado: (2018)

Chemical screen identifies shikonin as a broad DNA damage response inhibitor that enhances chemotherapy through inhibiting ATM and ATR
por: Wang, Fangfang, et al.
Publicado: (2022)

Sensitizing the Therapeutic Efficacy of Taxol with Shikonin in Human Breast Cancer Cells
por: Li, Wenjuan, et al.
Publicado: (2014)

Shikonin Inhibits Fin Regeneration in Zebrafish Larvae
por: Cao, Zigang, et al.
Publicado: (2022)

PAK1, PAK1Δ15, and PAK2: similarities, differences and mutual interactions
por: Grebeňová, Dana, et al.
Publicado: (2019)

A novel PAK4 inhibitor suppresses pancreatic cancer growth and enhances the inhibitory effect of gemcitabine
por: He, Hong, et al.
Publicado: (2021)

Computer-aided drug design, synthesis and identification of disulfide compounds as novel and potential allosteric PAK1 inhibitors
por: Huang, Hanwei, et al.
Publicado: (2018)

Shikonin as a WT1 Inhibitor Promotes Promyeloid Leukemia Cell Differentiation
por: Guo, Zhenzhen, et al.
Publicado: (2022)

Differential roles and regulation of the protein kinases PAK4, PAK5 and PAK6 in melanoma cells
por: Murugesan, Gavuthami, et al.
Publicado: (2022)

Anticancer Efficacy of Targeted Shikonin Liposomes Modified with RGD in Breast Cancer Cells
por: Wen, Xianchun, et al.
Publicado: (2018)

Evaluation of radical scavenging properties of shikonin
por: Yoshida, Lucia S., et al.
Publicado: (2014)

Promising Nanomedicines of Shikonin for Cancer Therapy
por: Yan, Chunmei, et al.
Publicado: (2023)

FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine
por: Yeo, Dannel, et al.
Publicado: (2016)

Integrative analysis of the shikonin metabolic network identifies new gene connections and reveals evolutionary insight into shikonin biosynthesis
por: Suttiyut, Thiti, et al.
Publicado: (2022)

Crystal Structures of the p21-Activated Kinases PAK4, PAK5, and PAK6 Reveal Catalytic Domain Plasticity of Active Group II PAKs
por: Eswaran, Jeyanthy, et al.
Publicado: (2007)

PAK1 Expression in Pancreatic Cancer: Clinicopathological Characteristics and Prognostic Significance
por: Symeonidis, Nikolaos, et al.
Publicado: (2019)

Shikonin promotes autophagy in BXPC-3 human pancreatic cancer cells through the PI3K/Akt signaling pathway
por: SHI, SHUQING, et al.
Publicado: (2014)

Endogenous nitric oxide accumulation is involved in the antifungal activity of Shikonin against Candida albicans
por: Liao, Zebin, et al.
Publicado: (2016)

PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis
por: Wang, Yonggang, et al.
Publicado: (2018)

Anticancer Efficacy of KRAS(G12C) Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS(G12C)-Mutant Pancreatic and Lung Cancers
por: Khan, Husain Yar, et al.
Publicado: (2023)

Shikonin enhances efficacy of a gene-based cancer vaccine via induction of RANTES
por: Chen, Hui-Ming, et al.
Publicado: (2012)

Shikonin potentiates paclitaxel antitumor efficacy in esophageal cancer cells via the apoptotic pathway
por: Du, Wenzhen, et al.
Publicado: (2019)

Natural compound Tan-I enhances the efficacy of Paclitaxel chemotherapy in ovarian cancer
por: Zhou, Jin, et al.
Publicado: (2020)

PAK Signaling in Oncogenesis
por: Molli, Poonam R., et al.
Publicado: (2009)

PAK signaling in cancer
por: Ye, Diana Zi, et al.
Publicado: (2012)

Crystal structure of SARS-CoV-2 main protease in complex with the natural product inhibitor shikonin illuminates a unique binding mode
por: Li, Jian, et al.
Publicado: (2021)

Expansion of BCR/ABL1 (+) cells requires PAK2 but not PAK1
por: Edlinger, Leo, et al.
Publicado: (2017)

PAK4 signaling in health and disease: defining the PAK4–CREB axis
por: Won, So-Yoon, et al.
Publicado: (2019)

PAK1 and PAK4 as therapeutic targets for Ewing sarcoma: a commentary
por: Parks, Sydney E., et al.
Publicado: (2021)

Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells
por: WADA, NAOKO, et al.
Publicado: (2014)

Simvastatin Ameliorates PAK4 Inhibitor-Induced Gut and Lung Injury
por: Pan, Shuming, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6q2kh1fi9uknj3b4ck9sjijvg6